Author

Jeffrey S. Bostwick

Observed names: Bostwick, Jeffrey, Bostwick, Jeffrey S., J S Bostwick, Jeffrey Bostwick, Jeffrey S Bostwick

Institution: Bristol-Myers Squibb (United States)

Observed institutions: Eli Lilly (United States), Bristol-Myers Squibb (United States), Bristol-Myers Squibb (United Kingdom)

OpenAlex ID: A5111509870

Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding

2017 · Pancras C. Wong, Dietmar Seiffert, et al. · Science Translational Medicine · 157

Antithrombotic and hemostatic effects of a small molecule factor XIa inhibitor in rats

2007 · William A. Schumacher, Steven E. Seiler, et al. · European Journal of Pharmacology · 90

Conformationally Constrained ortho-Anilino Diaryl Ureas: Discovery of 1-(2-(1′-Neopentylspiro[indoline-3,4′-piperidine]-1-yl)phenyl)-3-(4-(trifluoromethoxy)phenyl)urea, a Potent, Selective, and Bioavailable P2Y1 Antagonist

2013 · Jennifer X. Qiao, Tammy C. Wang, et al. · Journal of Medicinal Chemistry · 72

Discovery of 2-(Phenoxypyridine)-3-phenylureas as Small Molecule P2Y1 Antagonists

2013 · Hannguang Chao, Huji Turdi, et al. · Journal of Medicinal Chemistry · 68

Bleeding response induced by anti-thrombotic doses of a phosphoinositide 3-kinase (PI3K)-β inhibitor in mice

2011 · J. Eileen Bird, Patricia L. Smith, et al. · Thrombosis Research · 40

Biomarker Optimization to Track the Antithrombotic and Hemostatic Effects of Clopidogrel in Rats

2007 · William A. Schumacher, Jeffrey S. Bostwick, et al. · Journal of Pharmacology and Experimental Therapeutics · 39

Inhibition of Repetitive Thrombus Formation in the Stenosed Canine Coronary Artery by Enoxaparin, But Not by Unfractionated Heparin

1998 · Robert J. Leadley, Charles J. Kasiewski, et al. · Arteriosclerosis Thrombosis and Vascular Biology · 34

PDF

Effect of the Direct Factor Xa Inhibitor Apixaban in Rat Models of Thrombosis and Hemostasis

2010 · William A Schumacher, Jeffrey S Bostwick, et al. · Journal of Cardiovascular Pharmacology · 32

Antithrombotic efficacy of RPR208566, a novel factor Xa inhibitor, in a rat model of carotid artery thrombosis

2000 · Christopher Heran, Suzanne Morgan, et al. · European Journal of Pharmacology · 32

Discovery of a Hydroxypyridinone APJ Receptor Agonist as a Clinical Candidate

2021 · James A. Johnson, Soong-Hoon Kim, et al. · Journal of Medicinal Chemistry · 25

RG 12915: a potent 5-hydroxytryptamine-3 antagonist that is an orally effective inhibitor of cytotoxic drug-induced emesis in the ferret and dog.

1990 · L R Fitzpatrick, R M Lambert, et al. · Journal of Pharmacology and Experimental Therapeutics · 24

Biphenyl Acid Derivatives as APJ Receptor Agonists

2019 · Shun Su, Adam Clarke, et al. · Journal of Medicinal Chemistry · 22

Discovery of diarylurea P2Y1 antagonists with improved aqueous solubility

2013 · Tammy C. Wang, Jennifer X. Qiao, et al. · Bioorganic & Medicinal Chemistry Letters · 21

Identification of 1-{2-[4-chloro-1′-(2,2-dimethylpropyl)-7-hydroxy-1,2-dihydrospiro[indole-3,4′-piperidine]-1-yl]phenyl}-3-{5-chloro-[1,3]thiazolo[5,4-b]pyridin-2-yl}urea, a potent, efficacious and orally bioavailable P2Y1 antagonist as an antiplatelet agent

2014 · Yoon T. Jeon, Wu Yang, et al. · Bioorganic & Medicinal Chemistry Letters · 20

Pharmacodynamic Activity and Antithrombotic Efficacy of RPR120844, a Novel Inhibitor of Coagulation Factor Xa

1999 · Robert J. Leadley, Suzanne R. Morgan, et al. · Journal of Cardiovascular Pharmacology · 19

RPR120844, a Novel, Specific Inhibitor of Coagulation Factor Xa Inhibits Venous Thrombosis in the Rabbit

1999 · Ross Bentley, Suzanne Morgan, et al. · Thrombosis and Haemostasis · 19

PDF

Comparison of Enoxaparin, Hirulog, and Heparin as Adjunctive Antithrombotic Therapy during Thrombolysis with rtPA in the Stenosed Canine Coronary Artery

1997 · Robert J Leadley, Charles J Kasiewski, et al. · Thrombosis and Haemostasis · 19

Platelet Aggregometry and Receptor Binding to Predict the Magnitude of Antithrombotic and Bleeding Time Effects of Clopidogrel in Rabbits

2007 · Pancras C Wong, Earl J Crain, et al. · Journal of Cardiovascular Pharmacology · 18

Discovery of Potent and Selective Quinoxaline-Based Protease-Activated Receptor 4 (PAR4) Antagonists for the Prevention of Arterial Thrombosis

2024 · Xiaojun Zhang, Wen Jiang, et al. · Journal of Medicinal Chemistry · 16

Design of a New Class of Orally Active Fibrinogen Receptor Antagonists

1998 · Scott I. Klein, Bruce F. Molino, et al. · Journal of Medicinal Chemistry · 16

Anti-thrombotic activity of RG13965, a novel platelet fibrinogen receptor antagonist

1996 · Jeffrey S. Bostwick, Charles J. Kasiewski, et al. · Thrombosis Research · 16

Linking (Pyr)1apelin-13 pharmacokinetics to efficacy: Stabilization and measurement of a high clearance peptide in rodents

2018 · Joelle M. Onorato, Carrie Xu, et al. · Analytical Biochemistry · 15

Superiority of Enoxaparin Over Heparin in Combination With a GPIIb/IIIa Receptor Antagonist During Coronary Thrombolysis in Dogs

2001 · Sam S Rebello, Charles J Kasiewski, et al. · Thrombosis Research · 14

Identification of a Hydroxypyrimidinone Compound (21) as a Potent APJ Receptor Agonist for the Potential Treatment of Heart Failure

2021 · Wei Meng, Zulan Pi, et al. · Journal of Medicinal Chemistry · 13

4‐Benzothiazole‐7‐hydroxyindolinyl Diaryl Ureas Are Potent P2Y1 Antagonists with Favorable Pharmacokinetics: Low Clearance and Small Volume of Distribution

2014 · Jennifer X. Qiao, Tammy C. Wang, et al. · ChemMedChem · 13

Works count: 37

Citation count: 892

H-index: 18

I10-index: 27